Latest YDES news

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

GlobeNewsWire · Mon, 31 Aug 2026 18:00:00 -0400

TAIPEI, Taiwan, Aug. 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced its financial results for the six months ended June 30, 2026.

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

GlobeNewsWire · Tue, 25 Aug 2026 08:00:00 -0400

TAIPEI, Taiwan, Aug. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced the publication of a peer-reviewed review article in Nutrients, an international open-access journal published by MDPI (Multidisciplinary Digital Publishing Institute). The article, titled “Beyond Bone Health: Exploring the ‘Heart–Brain–Bone' Axis Modulated by Lipid-Soluble Nutrients (Omega-3, Vitamin D3, and Vitamin K2),” was co-authored by members of the Company's scientific team together with physicians associated with the Taiwan Chronic Disease Healthcare Association (“CDHA”), the Future Health Institute (“FHI”), and the Department of Neurosurgery at Taipei Medical University Hospital, among others.

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

GlobeNewsWire · Tue, 28 Jul 2026 08:00:00 -0400

The six-month pilot is designed to evaluate the potential scalability of bringing physician-ordered, blood-based OkaiDx laboratory-developed tests to patients in Canada Taipei, Taiwan, July 28, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced the launch of a six-month pilot collaboration (the “Pilot”) pursuant to that certain Pilot Service Agreement, dated as of July 23, 2026 (the “Agreement”), by and among YD Bio, YD Bio US Inc., a subsidiary of YD Bio (“YD Bio US”), EG BioMed US Inc., an affiliate of YD Bio (“EG BioMed US”), and Numia Health Inc., a British Columbia–based healthcare services provider (“Numia Health”), to establish a cross-border clinical workflow designed to support physician-ordered, blood-based cancer testing for eligible patients in British Columbia, Canada. Under the Agreement, the parties intend to evaluate an integrated clinical pathway that combines physician access, certified mobile blood collection, cross-border specimen logistics, and laboratory testing at EG BioMed US's CLIA-certified, CAP-accredited laboratory in Bothell, Washington (the “Laboratory”).

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

GlobeNewsWire · Thu, 23 Jul 2026 08:00:00 -0400

Taipei, Taiwan, July 23, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful conclusion of YD Bio's and its affiliate EG BioMed Co., Ltd.'s (“EG BioMed”) participation at BIO Asia-Taiwan 2026, an international industry conference held in Taiwan, at the Washington State Pavilion on July 19, 2026.

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

GlobeNewsWire · Thu, 02 Jul 2026 08:00:00 -0400

Taipei, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced that its affiliate, EG BioMed US Inc., a Delaware corporation (“EG BioMed US”), has obtained out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania for its CLIA-certified, CAP-accredited laboratory in Bothell, Washington (CLIA #50D2316600), reinforcing the Company's transition from a collection of technologies to a platform-based biotechnology company anchored in clinically derived molecular data.

YD Bio Limited Reports Full Year 2025 Financial Results

GlobeNewsWire · Thu, 30 Apr 2026 18:00:00 -0400

TAIPEI, Taiwan, April 30, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its financial results for the full year ended December 31, 2025.

YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States

GlobeNewsWire · Tue, 31 Mar 2026 08:00:00 -0400

Taipei, Taiwan, March 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company and EG BioMed Co., Ltd., a Taiwan registered company (“EG BioMed”), officially launched the EG Telehealth Platform, https://mdi.eg-bio.com , which marks a significant milestone in the Company's commercialization of early cancer detection and decentralized clinical service delivery across the United States.

Market information is provided for research and visualization and is not investment advice.